PARP9 and breast cancer: Survival analysis demonstrated a strong association between the overexpression of both BAL1 and BAL2 and favorable prognosis in patients with various subtypes of BC, including estrogen receptor (ER)-positive, ER-negative, Basal, luminal B, HER2-, and HER2 + subtypes.